Literature DB >> 18413657

Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines.

I M Anderson1, I N Ferrier, R C Baldwin, P J Cowen, L Howard, G Lewis, K Matthews, R H McAllister-Williams, R C Peveler, J Scott, A Tylee.   

Abstract

A revision of the 2000 British Association for Psychopharmacology evidence-based guidelines for treating depressive disorders with antidepressants was undertaken to incorporate new evidence and to update the recommendations where appropriate. A consensus meeting involving experts in depressive disorders and their management was held in May 2006. Key areas in treating depression were reviewed, and the strength of evidence and clinical implications were considered. The guidelines were drawn up after extensive feedback from participants and interested parties. A literature review is provided, which identifies the quality of evidence to inform the recommendations, the strength of which are based on the level of evidence. These guidelines cover the nature and detection of depressive disorders, acute treatment with antidepressant drugs, choice of drug versus alternative treatment, practical issues in prescribing and management, next-step treatment, relapse prevention, treatment of relapse, and stopping treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18413657     DOI: 10.1177/0269881107088441

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  102 in total

1.  The prognostic significance of subsyndromal symptoms emerging after remission of late-life depression.

Authors:  D N Kiosses; G S Alexopoulos
Journal:  Psychol Med       Date:  2012-05-21       Impact factor: 7.723

2.  [S3 guidelines on unipolar depression].

Authors:  M Bauer
Journal:  Nervenarzt       Date:  2010-09       Impact factor: 1.214

3.  Serotonin revisited.

Authors:  Philip J Cowen; Irwin Lucki
Journal:  Psychopharmacology (Berl)       Date:  2010-12-22       Impact factor: 4.530

4.  [Tricyclic antidepressants for initial treatment of depressive episodes? Con].

Authors:  M Adli; M Berger
Journal:  Nervenarzt       Date:  2016-05       Impact factor: 1.214

5.  A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Levomilnacipran ER 40-120mg/day for Prevention of Relapse in Patients with Major Depressive Disorder.

Authors:  Thomas Shiovitz; William M Greenberg; Changzheng Chen; Giovanna Forero; Carl P Gommoll
Journal:  Innov Clin Neurosci       Date:  2014-01

Review 6.  The efficacy and tolerability of bupropion in the treatment of major depressive disorder.

Authors:  Ricardo Moreira
Journal:  Clin Drug Investig       Date:  2011-10-19       Impact factor: 2.859

Review 7.  The promise and reality of pharmacogenetics in psychiatry.

Authors:  Peter P Zandi; Jennifer T Judy
Journal:  Psychiatr Clin North Am       Date:  2010-03

8.  Alternative calibration strategies for the clinical laboratory: application to nortriptyline therapeutic drug monitoring.

Authors:  Matthew T Olson; Autumn Breaud; Robert Harlan; Nkechinyere Emezienna; Sabitha Schools; Alfred L Yergey; William Clarke
Journal:  Clin Chem       Date:  2013-02-20       Impact factor: 8.327

Review 9.  Treatment resistant depression: strategies for primary care.

Authors:  Taylor C Preston; Richard C Shelton
Journal:  Curr Psychiatry Rep       Date:  2013-07       Impact factor: 5.285

10.  Explaining the rise in antidepressant prescribing: a descriptive study using the general practice research database.

Authors:  Michael Moore; Ho Ming Yuen; Nick Dunn; Mark A Mullee; Joe Maskell; Tony Kendrick
Journal:  BMJ       Date:  2009-10-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.